Edition:
United Kingdom

Michael Erman

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

18 Jan 2018

U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

17 Jan 2018

U.S. court invalidates patent on J&J cancer drug Zytiga

NEW YORK A U.S. administrative court on Wednesday invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.

17 Jan 2018

U.S. court invalidates patent on J&J cancer drug Zytiga

NEW YORK, Jan 17 A U.S. administrative court on Wednesday invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.

16 Jan 2018

Positive Keytruda lung cancer data sends Merck shares up 6 percent

Positive lung cancer results for Merck & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent.

03 Jan 2018

Allergan to cut over 1,000 jobs as it works to cut costs

NEW YORK Botox-maker Allergan Plc on Wednesday said it plans to cut over 1,000 jobs, more than 5 percent of its workforce, and eliminate an additional 400 currently open positions, as it works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.

02 Jan 2018

Drugmakers raise 2018 U.S. prices, stick to self-imposed limits

NEW YORK Drugmakers opened the new year by raising U.S. prices on dozens of medicines, but early data showed the increases generally remained within a 10 percent self-imposed limit in response to a backlash from consumers and politicians.

27 Dec 2017

Brigade Capital hedge fund criticizes Humana-Kindred deal

NEW YORK Hedge fund Brigade Capital Management, a top shareholder in Kindred Healthcare Inc , said on Wednesday the deal by U.S. health insurer Humana Inc and two private equity firms to buy Kindred was "disappointing and grossly inadequate."

19 Dec 2017

Tenet puts Conifer unit up for sale, plans more cost cuts

Tenet Healthcare Corp on Tuesday said it is putting its Conifer unit up for sale and plans to cut $100 million more in costs, as its new chief executive works to slash its heavy debt load.

13 Nov 2017

Allergan to sell a quarter of its Teva stake in first quarter 2018

NEW YORK Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

07 Nov 2017

Valeant profit beats forecasts on Bausch & Lomb strength

Valeant Pharmaceuticals International Inc reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye care business, sending its shares up more than 15 percent.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,730.79 + 29.83 +0.39%
DAX 13,434.45 + 153.02 +1.15%
CAC 40 5,526.51 + 31.68 +0.58%
TR Europe 197.16 + 1.25 +0.64%
GBP/USD 1.3857 +0.06%
GBP/EUR 1.1337 +0.00%
EUR/USD 1.2220 +0.00%
Gold 1,333.00 +7.00 +0.53%
Oil 63.57 -0.38 -0.59%
Corn 352.50 +1.00 +0.28%